|University of California, PhD|
Andreas Sommer, PhD joined the company following a successful 20-year career as a senior executive within both public and private biotechnology firms where he provided both executive operational and research leadership. Employed by Celtrix Pharmaceuticals, initially as senior Vice President Research and then as that company’s President and CEO, Dr. Sommer led a successful merger with Insmed, Inc. in association with an $80 million financing, leading to a multi-product company which saw its valuation increase from $300 million to over $900 million. Following the merger, as Chief Scientific Officer of Insmed, Dr. Sommer oversaw the NDA submission of Celtrix’s novel and complex recombinant protein Iplex™ to the U.S. Food and Drug Administration, resulting in its subsequent marketing approval, as well as four successful new orphan drug applications to the FDA and EMEA. He began his industry career as Vice President, Research and Development for BioGrowth, Inc. Dr. Sommer received his PhD in microbiology from the University of California, Davis.